CAS: 376653-43-9; (6R,7R)-7-((Z)-2-(5-Amino-1,2,4-Thiadiazol-3-yl)-2-(Hydroxyimino)Acetamido)-3-((E)-((R)-1'-(((5-Methyl-2-Oxo-1,3-Dioxol-4-yl)Methoxy)Carbonyl)-2-Oxo-[1,3'-Bipyrrolidin]-3-Ylidene)Methyl)-8-Oxo-5-Thia-1-Azabicyclo[4.2.0]Oct-2-Ene-2-Carboxylic Acid

该化合物是一种广泛的抗生素,主要用于治疗细菌感染,特别是抗抗菌菌株造成的菌感染,是一种青蒿素,意味着它被转化成体内活性体,即素.该复合物展示了一种独特的行动机制,对含有青霉素的蛋白质(PBPs)具有约束力,抑制细菌细胞壁合成,导致细胞分解和死亡.青霉素对各种抗乳腺阳性细菌和抗乳腺阴性细菌有效,包括抗抗抗甲菌素的抗血清菌菌素.它的青霉素特征可以有效施用抗毒剂,并典型地进行静脉注射.该物质具有稳定性,可以抑制某些抗抗菌性细菌菌素.Ceftobiplo medocaril对复杂的皮肤和软组织感染以及社区-后期性肺炎等疾病进行了临床评估,表明其在严重抗逆转录病毒治疗中可能出现严重性失常的慢性性感染.

英文名称(6R,7R)-7-((Z)-2-(5-Amino-1,2,4-Thiadiazol-3-yl)-2-(Hydroxyimino)Acetamido)-3-((E)-((R)-1'-(((5-Methyl-2-Oxo-1,3-Dioxol-4-yl)Methoxy)Carbonyl)-2-Oxo-[1,3'-Bipyrrolidin]-3-Ylidene)Methyl)-8-Oxo-5-Thia-1-Azabicyclo[4.2.0]Oct-2-Ene-2-Carboxylic Acid
中文名称头孢比普酯
IUPAC名称(6R,7R)-7-((Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(hydroxyimino)acetamido)-3-((E)-((R)-1'-(((5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy)carbonyl)-2-oxo-[1,3'-bipyrrolidin]-3-ylidene)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
其它别名Ceftobiprole Medocaril; 5-Thia-1-Azabicyclo[4.2.0]Oct-2-Ene-2-Carboxylicacid,7-[[(2Z)-2-(5-Amino-1,2,4-Thiadiazol-3-Yl)-2-(Hydroxyimino)Acetyl]Amino]-3-[[(E,3'R)-1'-[[(5-Methyl-2-Oxo-1,3-Dioxol-4-Yl)Methoxy]Carbonyl]-2-Oxo[1,3'-Bipyrrolidin]-3-Ylidene]Methyl]-8-Oxo-,(6R,7R)-; Ceftobiprole Medocaril Usp/ep/bp; 5-Thia-1-Azabicyclo[4.2.0]Oct-2-Ene-2-Carboxylicacid,7-[[(2Z)-2-(5-Amino-1,2,4-Thiadiazol-3-Yl)-2-(Hydroxyimino)Acetyl]Amino]-3-[[(E,3'R)-1'-[[(5-Methyl-2-Oxo-1,3-Dioxol-4-Yl)Methoxy]Carbonyl]-2-Oxo[1
CAS编号376653-43-9
MFCD编号:MFCD16621102
FDA UNII编号:YXV28V1B07
分子式:C26H26N8O11S2分子量:690.67
产品CID: 1387278
同类组份化合物CAS252188-71-9 (sodium)209467-52-7 (ceftobiprole)376653-43-9 (free acid)1209009-73-3 (sulfate)1209009-92-6 (phosphate)
产品分类原料药 → 抗生素类药物 → 头孢菌素类药

相似结构搜索
InChIKey: HFTSMHTWUFCYMJ-YIOMYIDASA-N
InChI=1S/C26H26N8O11S2/c1-10-14(45-26(41)44-10)8-43-25(40)32-4-3-13(7-32)33-5-2-11(20(33)36)6-12-9-46-22-16(21(37)34(22)17(12)23(38)39)28-19(35)15(30-42)18-29-24(27)47-31
计算化学: 氢键受体数17.0氢键供体数4.0可旋转键数9.0

物理性质

密度1.95
pKa:2.46±0.50(预测)
PSA:317.84
LogP:0.2474
储存条件Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
产品应用该化合物是一种青食食氯素的药物,是一种广泛频谱的甲状腺素抗生素抗生物,对抗甲西西林的抗血压球菌(MSA)和抗甲状菌素(VRSA)有效,对于皮肤和皮肤结构感染的复杂治疗有说明,加拿大和瑞士也批准了这一用途. 此外,还向欧洲药品署提交了肺炎治疗的销售许可申请.

上下游产品

头孢吡普 Ceftobiprole 209467-52-7

合成工艺路线路线简述

📜7-[2-(5-Amino-[1,2,4]Thiadiazol-3-yl)-2-Trityloxyimino-Acetylamino]-3-[1'-(5-Methyl-2-Oxo-[1,3]Dioxol-4-Ylmethoxycarbonyl)-2-Oxo-[1,3']Bipyrrolidinyl-3-Ylidenemethyl]-8-Oxo-5-Thia-1-Aza-Bicyclo[4.2.0]oct-2-Ene-2-Carboxylic Acid Benzhydryl Ester,三乙基硅烷置于乙醚体系中,用三氟乙酸用作溶剂,化学反应 0.25H,以to Yield 23 Mg Of The Title Compound As Beige Powder的收率获得头孢比普酯
参考文献:Process For The Preparation Of Vinyl-Pyrrolidinone Cephalosporin Derivatives
标题:Process For The Preparation Of Vinyl-Pyrrolidinone Cephalosporin Derivatives
摘要:本发明公开了一种制备式(i)的乙烯基吡咯烷酮头孢菌素衍生物的方法.同时也公开了式(II)中r1和r2定义的中间化合物.

海关参考信息

2901210000-乙烯
2901220000-丙烯
2901241000-1,3-丁二烯
2912110000-甲醛
💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
详情请参考：📖 海关编码查询和海关进出口税则

专利信息

专利号:US-9499566-B2
优先权日:2010-05-10
标题:Oxidation process for preparing 3-formyl-cephem derivatives
发明人：MARIA VERVEST IVAN JOSEPH
权利人:BASILEA PHARMACEUTICA INT
摘要:The present invention relates to an improved process for oxidizing 3-hydroxy-methyl-cephem derivatives to the corresponding 3-formyl-cephem derivatives. In particular this oxidation process is for the preparation of 7-[2-(5-amino-[1,2,4]thia-diazol-3-yl)-2-hydroxyimino-acetylamino]-3-formyl-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid derivatives of formula (I) using a combination of a hypervalent iodine oxidizing agent of the type 10-I-3 such as bis(acetoxy)iodo-benzene (BAIB) and a catalyst such as 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO). These compounds of formula (I) are intermediates in the synthesis of ceftobiprole.

其他信息查阅

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

实用工具

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献

1: Ramzy S, Alosaimi ME, Abduljabbar MH, Alnemari RM, Alatwi E, Almalki AH. Eco- Friendly Fluorescent Probe-Based Quantification of Ceftobiprole Medocaril: Greenness Assessment and Pharmacokinetic Study in Rats. Luminescence. 2025 Dec;40(12):e70393. doi: 10.1002/bio.70393. 69(12):e0127825. doi: 10.1128/aac.01278-25. Epub 2025 Nov 18.
3: Ceftobiprole medocaril (Zevtera) - a new cephalosporin antibiotic. Med Lett Drugs Ther. 2025 Sep 15;67(1737):149-152. doi: 10.58347/tml.2025.1737d. 14(8):1685-1696. doi: 10.1007/s40121-025-01174-7. Epub 2025 Jul 2.
5: McCarthy MW. Ceftobiprole medocaril for skin and skin-structure infections. Expert Opin Drug Metab Toxicol. 2025 May;21(5):519-523. doi: 10.1080/17425255.2025.2474127. Epub 2025 Mar 6. 59(7):657-665. doi: 10.1177/10600280241293773. Epub 2024 Dec 7. 81(19):e557-e560. doi: 10.1093/ajhp/zxae178. 46(8):659-660. doi: 10.1016/j.clinthera.2024.06.007. Epub 2024 Jul 14. 12(8):1337. doi: 10.3390/antibiotics12081337.